[go: up one dir, main page]

AR003132A1 - Derivados de n-hetero aril piridinsulfonamidas; composiciones farmaceuticas que los contienen; proceso para su preparacion y el uso de los mismos en la produccion de un medicamento - Google Patents

Derivados de n-hetero aril piridinsulfonamidas; composiciones farmaceuticas que los contienen; proceso para su preparacion y el uso de los mismos en la produccion de un medicamento

Info

Publication number
AR003132A1
AR003132A1 ARP960102899A AR10289996A AR003132A1 AR 003132 A1 AR003132 A1 AR 003132A1 AR P960102899 A ARP960102899 A AR P960102899A AR 10289996 A AR10289996 A AR 10289996A AR 003132 A1 AR003132 A1 AR 003132A1
Authority
AR
Argentina
Prior art keywords
nitrogen
substituted
alkoxy
alkyl
ring
Prior art date
Application number
ARP960102899A
Other languages
English (en)
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26307176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR003132(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9511507.7A external-priority patent/GB9511507D0/en
Priority claimed from GBGB9519666.3A external-priority patent/GB9519666D0/en
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of AR003132A1 publication Critical patent/AR003132A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se relaciona con compuestos farmacéuticamente útiles de la fórmula (I), en los que A, A2, A3, A4, B1 m, A, W, X, Y, Z y R1 adoptancualquiera de los siguientes significados. Uno entre A1, A2, A3 y A4 es nitrógeno y elre sto son CH, un grupo fenilo no sustituido o sustituido con 1,2 ó 3 sustituyentes seleccionados independientemente entre alquilo (C1-C6) no sustituido o sustituido con amino, hidroxi, carboxi, alcoxicarbonilo,alquilcarboniloxi, carbamoilo,carbamoil oxi, halógeno, alcoxi, sulfinilo, sulfonilo, cicloalquilo (C3-C8), fenilo; alcoxi, alquiltio; alquenilo (C2-C6);alquinilo (C2-C6); cicloalquilo todos sin sustituir o sustituidos; fenilo; fenoxi; mercapto; ciano; nitro; carbonilosustituido o no; benzoilo; sulfamoilosolo o sustituido, ureido, un grupo heterocíclico de 6 miembros que contiene 1, 2 ó 3 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno yazufre y un grupo -NRaRb en el cual Ra y Rb estánseleccionados e ntre hidrógeno alquilo (C1-C6) solo o sustituido o en conjunto el grupo -NRaRb completa unanillo 1-pirrolidinilo, 2-oxo-1-pirrolidinilo, 1-piperidinilo, 2-oxo-1- piperidinilo, morfolino o tiomorfolino; B1 es un sustituyenteoptativo en unátom o de carbono de A1, A2, A3 ó A4 seleccionado entre alquilo (C1-C4), halógeno y alcoxi (C1-C4); m es cero, 1, 2, ó 3; el anillo que contiene W, X,Yy Z y que contiene sustituyente R1 está seleccionado entre: (a) un anillo enel que W es nitróge no; X es CH; Y es nitrógeno; y Z es CRy, donde Ry es hidrógeno,halógeno, alquilo (C1-C4),alcoxi (C1-C4) o trifluorometoxi, (b) anillo donde W es CRz en el cual Rz es hidrógeno, halógeno, alquilo (C1-C4), alcoxi (C1-C4)otrifluorometoxi; X es nitróge no; Y es nitrógeno; y Z es CH; (c)un anillo en el cual W y X son ambos nitrógeno; y Y es CH; y Z es CRx, en el cual Rx es
ARP960102899A 1995-06-07 1996-06-04 Derivados de n-hetero aril piridinsulfonamidas; composiciones farmaceuticas que los contienen; proceso para su preparacion y el uso de los mismos en la produccion de un medicamento AR003132A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9511507.7A GB9511507D0 (en) 1995-06-07 1995-06-07 Heterocyclic compounds
GBGB9519666.3A GB9519666D0 (en) 1995-09-27 1995-09-27 Heterocyclic derivatives

Publications (1)

Publication Number Publication Date
AR003132A1 true AR003132A1 (es) 1998-07-08

Family

ID=26307176

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102899A AR003132A1 (es) 1995-06-07 1996-06-04 Derivados de n-hetero aril piridinsulfonamidas; composiciones farmaceuticas que los contienen; proceso para su preparacion y el uso de los mismos en la produccion de un medicamento

Country Status (31)

Country Link
US (3) US5866568A (es)
EP (1) EP0832082B1 (es)
JP (1) JP3193058B2 (es)
KR (1) KR100451523B1 (es)
CN (1) CN1097051C (es)
AR (1) AR003132A1 (es)
AT (1) ATE209200T1 (es)
AU (1) AU715041B2 (es)
BR (1) BR9608611A (es)
CA (1) CA2219742C (es)
CZ (1) CZ289387B6 (es)
DE (1) DE69617236T2 (es)
DK (1) DK0832082T3 (es)
EG (1) EG25227A (es)
ES (1) ES2168487T3 (es)
GE (1) GEP20053470B (es)
HR (1) HRP960272B1 (es)
HU (1) HUP9802300A3 (es)
IL (1) IL122464A (es)
MX (1) MX9709521A (es)
MY (1) MY114926A (es)
NO (1) NO314503B1 (es)
NZ (1) NZ308619A (es)
PL (1) PL187897B1 (es)
PT (1) PT832082E (es)
RU (1) RU2172738C2 (es)
SK (1) SK282338B6 (es)
TR (1) TR199701502T1 (es)
TW (1) TW340845B (es)
UA (1) UA58494C2 (es)
WO (1) WO1996040681A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5977117A (en) 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
AU717230B2 (en) 1996-02-20 2000-03-23 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
GB9614804D0 (en) * 1996-07-15 1996-09-04 Chiroscience Ltd Resolution process
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9704762D0 (en) * 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
TR200101905T2 (tr) 1997-04-28 2002-06-21 Texas Biotechnology Corporation Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler.
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
WO2000056685A1 (en) 1999-03-19 2000-09-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US6448239B1 (en) * 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
BR0016821A (pt) 1999-12-31 2002-12-10 Texas Biotechnology Corp Sulfonamidas e derivados da mesma que modulam a atividade de endotelina
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US7041280B2 (en) 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US6858592B2 (en) 2001-06-29 2005-02-22 Genzyme Corporation Aryl boronic acids for treating obesity
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
RU2234331C1 (ru) * 2002-12-30 2004-08-20 Смирнов Алексей Владимирович Лекарственное средство
US7169805B2 (en) * 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
KR100839512B1 (ko) * 2004-07-02 2008-06-19 주식회사 코오롱 설파제를 디아조화체로 하는 산성 항균 염료 및 그를이용한 항균 섬유
WO2006033446A1 (en) * 2004-09-21 2006-03-30 Astellas Pharma Inc. Aminoalcohol derivatives
US20090209492A1 (en) 2004-11-12 2009-08-20 Trustees Of Tufts College Lipase Inhibitors
US20070054325A1 (en) * 2005-04-14 2007-03-08 Reglia Materials and methods for screening modulators of neural regeneration
GB0514743D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Salt
HRP20120421T1 (hr) 2005-12-13 2012-07-31 Medimmune@Limited Vezni proteini specifični za inzulinu slične čimbenike rasta i njihova upotreba
CA2644578A1 (en) * 2006-03-03 2007-09-07 Torrent Pharmaceuticals Ltd Novel dual action receptors antagonists (dara) at the ati and eta receptors
MX2008013034A (es) * 2006-04-13 2008-10-17 Actelion Pharmaceuticals Ltd Antagonistas del receptor de endotelina para etapas tempranas de fibrosis pulmonar idiopatica.
RU2460729C2 (ru) * 2006-09-21 2012-09-10 Пирамал Лайф Сайнсиз Лимитед Производные 3-амино-пиридина для лечения метаболических нарушений
CL2008000191A1 (es) 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
CL2008001274A1 (es) 2007-05-03 2008-11-03 Intermune Inc Y Array Biopharma Inc Compuestos macrolidos derivados de 5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropan[e]pirrolo[1,2-a][1,4]diazaciclopentadecinilo, inhibidores de la actividad de la proteasa ns3-ns4; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios y procedimiento de preparacion; y uso en el tratamiento de.....
EA201000545A1 (ru) 2007-10-12 2010-10-29 Астразенека Аб Композиция зиботентана, содержащая маннит и/или микрокристаллическую целлюлозу
EP2297114B1 (en) 2008-06-19 2018-06-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
AU2010211672B2 (en) * 2009-02-06 2016-08-04 Nippon Shinyaku Co., Ltd. Aminopyrazine derivative and medicine
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
WO2020165226A1 (en) * 2019-02-12 2020-08-20 The University Court Of The University Of Glasgow Microvascular angina
US20230227477A1 (en) * 2020-06-25 2023-07-20 Wake Forest University Health Sciences Compounds for sensing reactive oxygen species and methods for using the same
US11730735B2 (en) 2020-07-10 2023-08-22 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases
AR126178A1 (es) 2021-06-22 2023-09-27 Alchemedicine Inc Compuesto, antagonista del receptor de endotelina a y composición farmacéutica
CA3264757A1 (en) 2022-08-12 2024-02-15 Astrazeneca Ab Polytherapy for the treatment of cirrhosis with portal hypertension
TW202446375A (zh) 2023-02-08 2024-12-01 瑞典商阿斯特捷利康公司 用於治療高蛋白尿慢性腎病的齊泊騰坦和達格列淨之組合
WO2025133907A1 (en) 2023-12-18 2025-06-26 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of microvascular angina
WO2025163559A1 (en) 2024-02-01 2025-08-07 Astrazeneca Ab Combination of zibotentan and dapagliflozin for use for the treatment of hypertension

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0655708B2 (ja) * 1985-05-13 1994-07-27 三井東圧化学株式会社 スルホンアミド系化合物及び農業用殺菌剤
UA13316A (uk) * 1986-01-31 1997-02-28 Ісіхара Сангіо Кайся Лтд Спосіб боротьби з hебажаhим ростом рослиh
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH04503672A (ja) * 1989-02-27 1992-07-02 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー 放射線増感剤としての新規なナフタレンスルホンアミド
TW270116B (es) * 1991-04-25 1996-02-11 Hoffmann La Roche
AU1929292A (en) * 1991-05-14 1992-12-30 Hybritech Incorporated Polymeric compositions having bound antibodies
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (es) * 1992-02-24 1994-06-01 Squibb & Sons Inc
AU678357B2 (en) * 1992-04-22 1997-05-29 Warner-Lambert Company Endothelin antagonists II
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
WO1994002474A1 (en) * 1992-07-17 1994-02-03 Smithkline Beecham Corporation Endothelin receptor antagonists
TW287160B (es) * 1992-12-10 1996-10-01 Hoffmann La Roche
EP0626174A3 (en) * 1993-04-21 1996-01-03 Takeda Chemical Industries Ltd Method and composition for the prophylaxis and / or treatment of underactive organs.
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
DE4426346A1 (de) * 1994-07-25 1996-02-01 Basf Ag Herbizide Pyrazinderivate
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
GB2295616A (en) * 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
EA007107B1 (ru) * 1995-04-04 2006-06-30 Инсизив Фармасьютикэлз Инк. Тиенил- и дифенилсульфонамиды и их производные, модулирующие активность эндотелина

Also Published As

Publication number Publication date
TW340845B (en) 1998-09-21
US6060475A (en) 2000-05-09
NO975700L (no) 1997-12-05
WO1996040681A1 (en) 1996-12-19
EP0832082A1 (en) 1998-04-01
RU2172738C2 (ru) 2001-08-27
EG25227A (en) 2011-11-17
US6258817B1 (en) 2001-07-10
EP0832082B1 (en) 2001-11-21
GEP20053470B (en) 2005-02-25
CZ388797A3 (cs) 1998-03-18
PT832082E (pt) 2002-04-29
SK282338B6 (sk) 2002-01-07
PL187897B1 (pl) 2004-10-29
CA2219742A1 (en) 1996-12-19
DE69617236D1 (de) 2002-01-03
NO975700D0 (no) 1997-12-05
KR19990022327A (ko) 1999-03-25
TR199701502T1 (xx) 1998-03-21
NZ308619A (en) 2000-01-28
ATE209200T1 (de) 2001-12-15
HUP9802300A2 (hu) 1999-10-28
CN1097051C (zh) 2002-12-25
AU715041B2 (en) 2000-01-13
UA58494C2 (uk) 2003-08-15
CN1192739A (zh) 1998-09-09
SK168097A3 (en) 1998-05-06
BR9608611A (pt) 1999-05-11
HRP960272A2 (en) 1997-08-31
US5866568A (en) 1999-02-02
AU5840396A (en) 1996-12-30
DE69617236T2 (de) 2002-07-11
HUP9802300A3 (en) 2002-02-28
PL324660A1 (en) 1998-06-08
CA2219742C (en) 2007-01-16
JPH11509175A (ja) 1999-08-17
MX9709521A (es) 1998-03-31
KR100451523B1 (ko) 2004-12-03
HK1005801A1 (en) 1999-01-29
IL122464A0 (en) 1998-09-15
CZ289387B6 (cs) 2002-01-16
MY114926A (en) 2003-02-28
NO314503B1 (no) 2003-03-31
ES2168487T3 (es) 2002-06-16
HRP960272B1 (en) 2006-06-30
JP3193058B2 (ja) 2001-07-30
IL122464A (en) 2002-05-23
DK0832082T3 (da) 2002-05-21

Similar Documents

Publication Publication Date Title
AR003132A1 (es) Derivados de n-hetero aril piridinsulfonamidas; composiciones farmaceuticas que los contienen; proceso para su preparacion y el uso de los mismos en la produccion de un medicamento
AR041009A1 (es) Compuestos heterociclicos nitrogenados que presentan actividad inhibitoria contra la integrasa del vih
HUP0301953A2 (hu) 1,5-Benzotiazepinek, eljárás előállításukra és felhasználásuk hiperlipidémia-ellenes szerekként
TW200745117A (en) Macrocylic inhibitors of hepatitis C virus
IL143806A0 (en) Pyrimidine compounds
HUP0103404A2 (hu) Oxazolidinonszármazékok, eljárás előállításukra, és az azokat tartalmazó gyógyászati készítmények
AU572405B2 (en) Heterocyclic-substituted indole
TW200716528A (en) Cyclopropanecarboxamide derivatives
HUP0401982A2 (hu) Indolizinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
GEP20084357B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
YU73300A (sh) Biciklični pirimidini i biciklični 3,4-dihidropirimidini kao inhibitori ćelijske proliferacije
AU1010692A (en) Novel phenylimidazolidines, process for their preparation, their use as medicaments and pharmaceutical compositions containing them
AU2003285584A8 (en) 3-(2-hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer
HUP9802865A2 (hu) N-(szubsztituált fenil-)-pirazol-származékok, előállításuk és alkalmazásuk, a vegyületeket hatóanyagként tartalmazó parazitaellenes készítmények
ES8202334A1 (es) Un procedimiento para la preparacion de derivados de 2,4-diaminoquinazolina
IL161559A0 (en) Dibenzylamine derivatives and pharmaceutical compositions containing the same
HUT71482A (en) 4,1-benzoxazepine derivatives, process for preparing them and pharmaceutical compositions containing them
HUP0001294A2 (hu) Proteáz inhibitor hatású (heterociklil-karbonil)-hidrazid-származékok, eljárás előállításukra és alkalmazásuk
EP0366304A3 (en) Heterocyclic derivatives, process for their preparation and pharmaceutical compositions containing them
JO1255B1 (en) Various compounds loops
AU8997898A (en) Epoxysuccinamide derivatives
AU2003249484A1 (en) Novel bio-active molecules
AU6894896A (en) Indazolecarboxamides
MY140653A (en) Substituted diketopiperazines and their use as oxytocyn antagonists
HUP0500164A2 (hu) Heterociklussal szubsztituált benzolszulfonamidok mint HIV proteáz inhibitorok és az ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FG Grant, registration